Log in Demo Start free trial

S-1 primary document

HCWB · Registration Statement (Form S-1) · Filed August 20, 2026

Hcw Biologics Inc — S-1 exhibit

ex107.htm

Hcw Biologics Inc on Boardroom Alpha

EX-FILING FEES

Calculation of Filing Fee Tables
S-1
HCW Biologics Inc.

Table 1: Newly Registered and Carry Forward Securities	☐Not Applicable

		Security Type	Security Class Title	Fee Calculation or Carry Forward Rule	Amount Registered	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee	Carry Forward Form Type	Carry Forward File Number	Carry Forward Initial Effective Date	Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward
Newly Registered Securities
Fees to be Paid	1	Equity	Common Stock, par value $0.0001 per share	Other	618,682	$ 2.55	$ 1,577,639.10	0.0001381	$ 217.87
Fees to be Paid	2	Equity	Pre-Funded Warrants	Other				0.0001381	$ 0.00
Fees to be Paid	3	Equity	Common Stock Underlying Pre-Funded Warrants	Other				0.0001381	$ 0.00
Fees to be Paid	4	Equity	Common Warrants	Other				0.0001381	$ 0.00
Fees to be Paid	5	Equity	Common Stock underlying Common Warrants	Other	618,682	$ 2.585	$ 1,599,292.97	0.0001381	$ 220.86
Fees Previously Paid
Carry Forward Securities
Carry Forward Securities
			Total Offering Amounts:				$ 3,176,932.07		$ 438.73
			Total Fees Previously Paid:						$ 0.00
			Total Fee Offsets:						$ 0.00
			Net Fee Due:						$ 438.73

Offering Note

¹	Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the shares of Common Stock being registered hereby include an indeterminate number of shares of Common Stock that may be issuable as a result of stock splits, stock dividends or similar transactions. The shares of Common Stock being registered for resale consist of (i) 218,682 shares of Common Stock issued in the July 2026 private placement and (ii) 400,000 shares of Common Stock issuable upon exercise of pre-funded warrants issued in the July 2026 private placement. Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities Act based on the average of the high and low sale prices of the registrant's Common Stock on The Nasdaq Capital Market on August 18, 2026. The registrant will not receive any proceeds from the sale of the shares of Common Stock by the selling stockholders.

²	Represents 400,000 Pre-Funded Warrants issued in the July 2026 Private Placement. Pursuant to Rule 457(g) under the Securities Act, because the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants are being registered hereby, no separate registration fee is payable with respect to the pre-funded warrants.

³	Pursuant to Rule 416 under the Securities Act, the shares of Common Stock being registered hereby include an indeterminate number of shares of Common Stock that may be issuable as a result of stock splits, stock dividends or similar transactions. Represents 400,000 shares of Common Stock issuable upon exercise of pre-funded warrants issued in the July 2026 Private Placement. No additional registration fee is due with respect to such shares because the registration fee attributable thereto is reflected in the fee paid for the Common Stock registered pursuant to footnote (1).

⁴	Represents up to 618,682 common stock purchase warrants issuable pursuant to the Securities Purchase Agreement entered into in connection with the July 2026 Private Placement, subject to stockholder approval under Nasdaq Listing Rule 5635(d). Pursuant to Rule 457(g) under the Securities Act, because the shares of Common Stock issuable upon exercise of the Common Warrants are being registered hereby, no separate registration fee is payable with respect to the Common Warrants.

⁵	Pursuant to Rule 416 under the Securities Act, the shares of Common Stock being registered hereby include an indeterminate number of shares of Common Stock that may be issuable as a result of stock splits, stock dividends or similar transactions. Represents 618,682 shares of Common Stock issuable upon exercise of common stock purchase warrants issuable in the July 2026 Private Placement, subject to stockholder approval under Nasdaq Listing Rule 5635(d). Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(g) under the Securities Act based upon the exercise price of $2.585 per share of the Common Warrants.

Table 2: Fee Offset Claims and Sources	☑Not Applicable

		Registrant or Filer Name	Form or Filing Type	File Number	Initial Filing Date	Filing Date	Fee Offset Claimed	Security Type Associated with Fee Offset Claimed	Security Title Associated with Fee Offset Claimed	Unsold Securities Associated with Fee Offset Claimed	Unsold Aggregate Offering Amount Associated with Fee Offset Claimed	Fee Paid with Fee Offset Source
Rules 457(b) and 0-11(a)(2)
Fee Offset Claims
Fee Offset Sources
Rule 457(p)
Fee Offset Claims
Fee Offset Sources

Table 3: Combined Prospectuses	☑Not Applicable

	Security Type	Security Class Title	Amount of Securities Previously Registered	Maximum Aggregate Offering Price of Securities Previously Registered	Form Type	File Number	Initial Effective Date

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer